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ABSTRACT 
Background: Evidence from observational studies of telomere length (TL) has been conflicting 
regarding its direction of association with cancer risk. We investigated the causal relevance of TL for 
lung and head and neck cancers using Mendelian Randomization (MR) and mediation analyses. 
Methods: We developed a novel genetic instrument for TL in chromosome 5p15.33, using variants 
identified through deep-sequencing, that were genotyped in 2051 cancer-free subjects. Next, we 
conducted an MR analysis of lung (16396 cases, 13013 controls) and head and neck cancer (4415 
cases, 5013 controls) using 8 genetic instruments for TL. Lastly, the 5p15.33 instrument and distinct 
5p15.33 lung cancer risk loci were evaluated using two-sample mediation analysis, to quantify their 
direct and indirect, telomere-mediated, effects. 
Results: The multi-allelic 5p15.33 instrument explained 1.49-2.00% of TL variation in our data 
(p=2.6×10-9). The MR analysis estimated that a 1000 base pair increase in TL increases risk of lung 
cancer (OR=1.41, 95% CI: 1.20-1.65) and lung adenocarcinoma (OR=1.92, 95% CI: 1.51-2.22), but 
not squamous lung carcinoma (OR=1.04, 95% CI: 0.83-1.29), or head and neck cancers (OR=0.90, 
95% CI: 0.70-1.05).  Mediation analysis of the 5p15.33 instrument indicated an absence of direct 
effects on lung cancer risk (OR=1.00, 95% CI: 0.95-1.04). Analysis of distinct 5p15.33 susceptibility 
variants estimated that TL mediates up to 40% of the observed associations with lung cancer risk.  
Conclusions: Our findings support a causal role for long telomeres in lung cancer etiology, 
particularly for adenocarcinoma, and demonstrate that telomere maintenance partially mediates the 
lung cancer susceptibility conferred by 5p15.33 loci.  
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KEY MESSAGES 
x Genetic predisposition to long telomeres increases risk of lung cancer, predominately lung 
adenocarcinoma  
x Genetic determinants of long telomeres are not associated with squamous carcinomas of the 
lung or head and neck 
x Using two-sample mediation analysis we determined that the novel 5p15.33 instrument for 
telomere length does not have direct effects on the outcome, and demonstrated that the 
association between 5p15.33 lung cancer susceptibility variants is partially mediated by 
telomere length, suggesting the presence of other relevant mechanisms  
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INTRODUCTION 
Telomeres are highly conserved stretches of tandem repeats of the TTAGGG sequence, 
which protect chromosome ends from degradation and maintain genome stability(1, 2). Due to the 
incomplete replication of chromosomes during cell division, human telomeres lose between 50 and 
200 base pairs with each replication(1-3). In checkpoint proficient cells critically short telomeres 
trigger senescence, followed by apoptosis, which represents a barrier against cancer initiation by 
limiting cellular proliferation(4, 5). As telomeres shorten their ability to maintain chromosomal stability 
also diminishes, which may increase cancer susceptibility(6, 7). However, long telomeres may also 
promote cancer development through an accumulation of mutations due to prolonged cell survival 
and proliferation. In fact, cancer cells are characterized by such a proliferative advantage, often 
through reactivation of telomerase, which is normally silent in somatic cells(4, 5, 8).  
Telomere length (TL) has been studied extensively in relation to cancer risk. However, 
findings of epidemiologic studies have been conflicting (6, 9-11). Observational studies investigating 
TL measured after cancer diagnosis are particularly vulnerable to reverse causation and residual 
confounding, therefore shorter TL observed in cancer cases is likely to reflect underlying disease or 
the impact of cancer treatment (12, 13). It is also difficult to isolate the influence of TL on cancer risk 
from that of other risk factors that influence both TL and cancer susceptibility, including biological or 
replicative age (10, 14, 15).  
Mendelian Randomization (MR) is an approach for evaluating causality by using single 
nucleotide polymorphisms (SNPs) in relevant genes as instrumental variables (IVs) (16). Genome-
wide association studies (GWAS) identified a number of genetic regions involved in TL regulation, 
including genes encoding the catalytic subunit of telomerase (TERT) in chromosome 5p15.33 and its 
RNA template (TERC) in 3q26.2 (17-21). By leveraging these associations, MR can provide a valid 
test of the causal hypothesis assuming the genetic IVs only affect cancer risk through TL regulation. 
Previous studies using genetic proxies for TL suggest that longer telomeres confer an 
increased risk of lung cancer, especially adenocarcinoma (22-24), which is consistent with the 
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findings of prospective observational studies (25-27). Lung cancer case-control studies report both 
increased (28) and inverse (6, 29) associations for long TL, and some implicate high TL variability in 
lung cancer susceptibility (30). For head and neck cancers (HNC), which are predominantly 
squamous carcinomas, short TL is consistently associated with increased risk in case-control studies 
(6, 31, 32), whereas a recent MR analysis (24) did find evidence supporting a causal relationship.  
The overarching aim of this study is to investigate the causal relationship between TL and 
risk of lung and upper aero-digestive tract cancers. First, we developed a novel genetic instrument 
for TL in chromosome 5p15.33, given the extensive pleiotropy in this region and potential for violating 
MR assumptions (22, 33). Next, we conducted the largest two-sample MR analysis of lung and HNC 
risk to date. Lastly, we quantified the direct and telomere-mediated effects of 5p15.33 genetic variants 
on cancer risk using a two-sample mediation analysis approach (Figure 1).  
METHODS 
Study populations 
We used individual-level data from 23 pooled studies of lung cancer, with 16396 cases (5690 
adenocarcinoma, 4045 squamous carcinoma) and 13013 controls; and 11 HNC studies with 4415 
cases and 5013 controls, all part of the OncoArray collaboration (34) (Supplementary Tables 1-2). 
Descriptions of studies and genotyping methods have been previously published (34, 35) (details in 
Supplementary File 1). Analyses were restricted to individuals of predominantly European ancestry 
(80% lung, >70% HNC)(34, 36). Studies received approval from institutional research ethics review 
boards and informed consent was obtained from the participants.  
The novel 5p15.33 instrument was developed using data from two studies: the cancer-free 
controls from the Mount Sinai and Princess Margaret Hospital (MSH-PMH) case-control study in 
Toronto(37), and cancer-free individuals from the Copenhagen General Population Study 
(CGPS)(38), a population-based prospective cohort (Table 1). TL was measured in DNA from 
peripheral blood leukocytes using previously described quantitative polymerase chain reaction 
assays performed in MSH-PMH (37) and CGPS (23, 38) (details in Supplementary File 2). 
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Statistical Analysis 
Mendelian randomization analysis 
 The genetic instruments for TL included independent SNPs showing strong prior evidence of 
association with TL, such as p<5×10-8 in the discovery stage of at least one GWAS and replication in 
a separate GWAS or meta-analysis (17-21). In addition to the new 5p15.33 instrument described 
below, we selected 7 additional loci involved in telomere maintenance: rs10165485 (proxy for 
rs11125529, r2=1.0) in ACYP2 (2p16.2), rs6772228 in PXK (3p14.3), rs10936599 in TERC (3q26.2), 
rs11100479 (proxy for rs7675998, r2=0.99) in NAF1 (4q32.2), rs9420907 in OBFC1 (10q24.3), 
rs10419926 in ZNF676 (19p12), and rs755017 near RTEL1 and ZBTB46 (20q13).  Only genotyped, 
non-imputed variants were used. 
For the purpose of developing a new instrument in the 5p15.33 region, TL values were 
converted to Z-scores in MSH-PMH (n=879) and CGPS (n=1172) studies separately, and pooled to 
increase statistical power. Linear regression was used to estimate the association between 899 
variants in 5p15.33 and TL, adjusting for age, sex, study, and the top 5 genetic ancestry principal 
components (PCs).  
Selection of variants for the 5p15.33 instrument was based on statistical significance, 
consistency across the two studies, and instrument strength, measured by the F statistic, which 
depends on the variance in TL explained by the genetic predictors (R2), sample size (n), and number 
of instruments (k): ܨ ൌ ቀ௡ି௞ିଵ௞ ቁ ቀ ோమଵିோమቁǤ Variants were considered for inclusion in the 5p15.33 
instrument if they met the following criteria: 
i. F5 and p<0.05 in the Toronto and Copenhagen combined dataset (n=2051) 
ii. F<5 and p<0.05 overall (n=2051) and F>5 among never smokers (n=848) 
iii. Consistent direction of allelic effects in MSH-PMH and CGPS 
iv. Minor allele detected in at least 2 individuals 
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Independent genetic variants (r2<0.2) that met the selection criteria were combined into an allele 
score representing the 5p15.33 region to increase the power of the resulting instrument (39, 40). 
The MR analysis combined summary statistics across the genetic IVs to estimate the causal 
parameter , which is the log odds ratio (OR) describing the causal effect of increasing TL on 
cancer risk (Supplementary Figure 1).  Parameters for the MR analysis included  and , where 
 is a vector of SNP-TL associations and is a vector of per-allele cancer log ORs for each 
instrument. For genetic instruments outside of 5p15.33, and corresponding standard errors (SE) 
were obtained from the literature and scaled to represent a 1000 base pair (kbp) increase in leukocyte 
TL, a proxy for TL in relevant tissues(19-21). For all instruments, and corresponding SE were 
estimated directly using individual-level OncoArray lung and HNC data. Logistic regression models 
were adjusted for age, sex, study, and 10 PCs. 
The causal parameter  was estimated using the maximum likelihood-based (ML) 
approach and the inverse-variance weighted (IVW) method (41, 42). This was complemented by 
sensitivity analyses using the weighted median estimator (WME), which provides valid estimates of 
the causal parameter even when up to 50% of the statistical weights are contributed by genetic 
instruments violate MR assumptions (43).  
Mediation analysis 
The aim of the mediation analysis was to quantify how much of the lung cancer association 
in the 5p15.33 region is mediated by TL. First, we validated the 5p15.33 instrument by decomposing 
its total effect on lung cancer into direct and indirect effects, mediated by TL. Next, we extended this 
analysis to independent (r2<0.20) variants that capture the lung cancer association signal in 5p15.33 
(details in Supplementary File 3).  
Our mediation approach is based on the counterfactual framework(44, 45) and extends the 
sensitivity analysis using two randomized controlled trials proposed by Vanderweele, which allows 
b
IV
b
TL
b
Y
b
TL
b
Y
b
TL
b
Y
b
IV
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the mediator-outcome ( ) and exposure-mediator ( ) relationships to be estimated in separate 
studies (46). Application of this approach in the present context assumes that a valid estimate for the 
mediator-outcome relationship can be obtained from an independent MR or cohort studies. Based on 
previously published formulas for mediation analysis (44, 45), the total effect (TE) of increasing the 
exposure from reference level a* to level a on lung cancer (ܻ) conditional on covariates c can be 
decomposed into natural direct effects (NDE) and natural indirect effects (NIE): ܱܴ௔ǡ௔כȁ௖்ா ൌ ܲሺ ௔ܻ ൌ  ?ȁܿሻȀሼ ? െ ሺܲ ௔ܻ ൌ  ?ȁܿሻሽܲሺ ௔ܻכ ൌ  ?ȁܿሻȀሼ ? െ ሺܲ ௔ܻכ ൌ  ?ȁܿሻሽ ൌ ܱܴ௔ǡ௔כȁ௖ேூா ൈ ܱܴ௔ǡ௔כȁ௖ே஽ா ሺ ?ሻ 
Assuming a rare outcome and absence of exposure-mediator interaction, mediated effects are 
given by: ܱܴ௔ǡ௔כȁ௖ேூா ൎ ሼߠଶ ൈ ߚଵሺܽ െ ܽכሻሽሺ ?ሻ 
where is log-OR per one unit increment in TL and is the effect of the 5p15.33 instrument on TL. 
Based on equation 1, NDE can be obtained by subtracting the NIE from the total effect: ሺܱܴ௔ǡ௔כȁ௖ே஽ா ሻ ൎ ሺܱܴ௔ǡ௔כȁ௖்ா ሻ െ  ሺܱܴ௔ǡ௔כȁ௖ேூா ሻሺ ?ሻ 
In the presence of interaction between the exposure and mediator, the NIE is given by: ܱܴ௔ǡ௔כȁ௖ேூா ൎ ሼሺߠଶ ൈ ߚଵ ൅ ߠଷ ൈ ߚଵܽሻ ൈ ሺܽ െ ܽכሻሽሺ ?ሻ 
where now represents the main effect of the mediator, TL, and  is the exposure-mediator 
interaction parameter, with NDE having a more complicated form given by Valeri and 
VanderWeele(45). Formulas for a dichotomized mediator are provided in Supplementary File 4. 
The  parameter for the 5p15.33 instrument is equivalent to  estimated in the cancer-
free subset of the MSH-PMH and CGPS studies, adjusting for appropriate covariates. For 5p15.33 
cancer susceptibility variants, estimates were selected from Bojesen et al. (47), the largest fine-
mapping analysis of common 5p15.33 loci and TL with 15567 cancer-free controls. Per allele 
associations were reported as percent increase in TL and base-pair change. ORTE for all variants was 
estimated in 23 lung cancer OncoArray studies, and is equivalent to for the 5p15.33 instrument.  
q 2 b 1
q 2 b 1
q 2 q 3
b 1 b TL
b
1
b
Y
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External estimates of the mediator-outcome relationship ( ) were substituted into the 
equation (2) to avoid estimating the effect of TL on lung cancer risk directly using MSH-PMH case-
control data, which are likely to be biased due to the post-diagnostic timing of TL measurement. The 
effect of TL on lung cancer risk was obtained from two studies: an MR analysis TL by Zhang et al.(22), 
and a meta-analysis of prospective studies by Zhu et al. (11) (Supplementary Figure 2).  
Since interaction between the 5p15.33 instrument and TL is plausible, we conducted 
sensitivity analyses under different magnitudes of 
 
(details in Supplementary File 4). Confidence 
intervals for the NIE and NDE were approximated as Bayesian credible intervals. Analyses were 
conducted using R version 3.3.3. 
RESULTS 
Characteristics of the combined Toronto and Copenhagen dataset (n=2051), used to develop 
the 5p15.33 instrument, are summarized in Table 1. The cancer-free participants in the MSH-PMH 
and CGPS studies were of similar mean age, 61.0 and 61.30 years, respectively. Age was the 
strongest predictor of TL (p=2.6×10-30), while sex, smoking status, and cigarette pack-years among 
smokers were not associated with relative TL (Supplementary Table 3).  
Novel 5p15.33 instrument for telomere length 
The 5p15.33 variants comprising this instrument were not used in any previous MR studies 
of TL. After excluding 17 singletons and other SNPs that did not meet our criteria, 14 variants were 
included in the multi-allelic instrument for 5p15.33 (Table 2; regional plot and LD illustrated in 
Supplementary Figure 3). Most variants were located in non-coding intronic regions of several genes, 
including SLC6A3, TERT, LPCAT1, and a long-noncoding RNA (LINC01511) except for rs35033501, 
a synonymous TERT variant. The resulting multi-allelic 5p15.33 IV accounted for 1.49% of variation 
in the telomere Z-score in all subjects (F = 35.83; = 0.14, SE=0.02) and 2.00% in never smokers 
(F = 20.81), but was not predictive of smoking status (p=0.19) or cigarette pack-years among smokers 
(p=0.59) (Table 3). The 5p15.33 instrument was positively associated with lung cancer (OR=1.04, 
q 2
q 3
b
TL
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95% CI: 1.01-1.07) and lung adenocarcinoma (OR=1.06, 1.03-1.10), but not squamous lung 
carcinomas (OR=1.03, 0.98-1.07). An inverse association was observed for HNC (OR=0.95, 0.90-
1.00) and oral cavity cancer (OR=0.93, 0.87-0.98). 
Telomere length and cancer risk 
Results of the MR analysis based on 8 genetic instruments are presented in Table 4 and 
Figure 2. The likelihood-based model estimated a 41% increase in lung cancer risk per kbp increase 
in TL (ORML=1.41, 95% CI: 1.20-1.65). Estimates of the causal OR for lung cancer remained 
consistent across MR estimation methods. Genetic determinants of TL were predominantly 
associated with adenocarcinoma (ORML=1.92, 1.51-2.45), and appeared unrelated to squamous 
carcinoma (ORML=1.04, 0.83-1.29) and small cell carcinoma (ORML=1.03, 0.76-1.39). 
The effect of long TL on lung cancer risk was larger in magnitude among never smokers  
(ORML=1.78, 1.22-2.61) compared to smokers (ORML=1.36, 1.14-1.63), although the former was 
attenuated in sensitivity analyses (ORWME=1.55, 95% CI: 0.98-2.46). Effects on adenocarcinoma risk 
were also substantial in never smokers (ORML=2.68, 1.70-4.24). Genetic determinants of long 
telomeres conferred a 68% increase in lung cancer risk (ORML=1.68, 1.07-2.62) in subjects aged 50 
years or younger. In contrast to lung cancer, genetic predisposition for longer TL did not seem related 
to risk of HNC overall (ORML= 0.90, 0.70-1.05), oral cavity (ORML=0.88, 0.65-1.19) and oropharynx 
cancers (ORML=0.83, 0.59-1.16).  
Several additional sensitivity analyses were undertaken to further interrogate the MR results. 
Since smoking is an established risk factor for both HNC and lung cancer, MR analyses were 
repeated with adjustment for cigarette pack-years and smoking status. No appreciable changes were 
observed in the causal effect estimates for lung cancer overall (ORML=1.50, 1.27-1.78), lung 
adenocarcinoma (ORML=1.95, 1.53-2.49), HNC (ORML=0.91, 0.67-1.23), oral cavity (ORML=0.82, 
0.57-1.18) or oropharynx cancers (ORML=0.86, 0.57-1.31).  
The potential for directional pleiotropy was evaluated by checking for asymmetry in the plots 
depicting ratio estimates for each instrument, , plotted against instrument strength, 
b
Y
b
TL
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 (Supplementary Figure 4). These results were not suggestive of pleiotropy and none of 
the genetic instruments were associated with cigarette smoking status or pack-years (Supplementary 
Table 4). Lastly, selected causal effects were re-estimated using the weighted mode-based estimator 
(MBE), which is robust to horizontal pleiotropy when the largest number of similar causal effect 
estimates are based on valid instruments, even if the majority of instruments are invalid (48). 
Estimates for lung cancer overall (ORMBE=1.34, 1.08-1.66), lung adenocarcinoma (ORMBE=1.55, 1.14-
2.12), and adenocarcinoma in never smokers (ORMBE=2.04, 1.04-4.04), were consistent with the 
primary results in Table 4. 
Mediation analysis of the 5p15.33 instrument 
We conducted mediation analyses to quantify direct (ORNDE) and indirect effects (ORNIE) of 
the 5p15.33 instrument on lung cancer. The ORNIE we report is the proportional change in the odds 
of lung cancer for a change in TL that occurs when the 5p15.33 allele score increases by one from 
the reference level, corresponding to the mean of the allele score distribution. The estimate of the TL 
effect on lung cancer ( ) was selected from the strict model reported by Zhang et al.(22) (OR per 
kbp increase: 1.37, 95% CI: 1.12-1.68), which excluded rs2736100 (TERT). ORTE for the 5p15.33 IV 
was re-estimated after removing overlapping subjects (n=3498) between the OncoArray and Zhang 
et al.(22). Assuming no interaction between the 5p15.33 IV and TL, the lung cancer effect appeared 
to be almost entirely mediated by TL (ORNIE=1.05, 1.01-1.08), whereas the direct effects of the 
5p15.33 IV appeared null (ORNDE=1.00, 0.95-1.04) (Figure 3; Supplementary Table 5). For lung 
adenocarcinoma, the 5p15.33 effects mediated by TL were larger in magnitude (ORNIE=1.11, 1.05-
1.18) than direct effects, which were close to unity (ORNDE=0.97, 0.90-1.03). 
Interaction sensitivity analyses for the NIE and NDE were carried out across three levels of 
: 0.10, 0.20 and 0.30. As the magnitude of the interaction parameter increased, so did the NIE, 
while TL-independent effects were not observed (Figure 3). Indirect effects on lung cancer risk 
mediated by TL ranged from ORNIE=1.06 (95% CI: 1.03-1.10) for =0.10, to ORNIE=1.09 (95% CI: 
b
TL
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)
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1.05-1.15) for = 0.30. For adenocarcinoma, increasing the magnitude of interaction between the 
5p15.33 IV and TL was also associated with increasing NIE and diminishing direct effects. 
The prospective meta-analysis estimate of from Zhu et al.(11) reported an OR of 1.28 
(95% CI: 1.09-1.50) for lung cancer comparing long vs. short TL. Based on this binary mediator, the 
NIE mediated by TL was attenuated, but remained statistically significant (ORNIE=1.01, 1.00-1.03). A 
positive direct effect on lung cancer risk was also observed (ORNDE=1.03, 1.00-1.06). Assuming 
interaction between the 5p15.33 instrument and TL, the mediated effects ranged from ORNIE=1.02 
(95% CI: 1.01-1.03) when =0.10, to ORNIE=1.03 (95% CI: 1.01-1.05) when =0.30, while the direct 
effects decreased (Figure 3; Supplementary Table 5). 
Mediation analysis of 5p15.33 lung cancer susceptibility loci 
Five common (MAF>0.05), independent (r2 <0.20) variants were selected to represent the 
lung cancer susceptibility signal in 5p15.33 (details in Supplementary File 3): rs7705526 
(PAdeno=4.6×10-13; PLung=8.0×10-7), rs2736108 (PAdeno=1.7×10-12; PLung=1.8×10-11), rs421629 
(PAdeno=6.2×10-9; PLung=1.2×10-16), rs13167280 (PAdeno=1.4×10-8; PLung=1.1×10-6), and rs56345976 
(PAdeno=2.2×10-7; PLung=3.6×10-9). These variants have been associated with lung cancer and lung 
adenocarcinoma in previous studies (37, 49-51), and are representative of the genetic susceptibility 
architecture in this region.  
Estimates of  were obtained from Bojesen et al.(47), and three TERT lung cancer risk 
variants were significantly associated with TL: rs7705526 (PTL=2.3×10-14), rs2736108 (PTL=5.8×10-7), 
and rs13167280 (PTL=1.2×10-5). Estimates of were selected from the MR analysis (22) and ORTE 
were re-estimated for each variant after removing the overlapping subjects. For all variants, the TL-
increasing allele was positively associated with cancer risk, and both direct and indirect, TL-mediated 
effects were significant (Supplementary Table 6).  
For lung cancer, the proportion mediated (PM) by TL was the largest for rs13167280 
(ORNIE=1.05, 1.03-1.07; PM=40.5%), followed by rs7705526 (ORNIE=1.03, 1.01-1.05; PM=28.7%) 
q 3
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and rs2736108 (ORNIE 1.02, 1.01-1.03; PM=13.7%). The magnitude and proportion of the SNP effects 
that were mediated by TL were larger for adenocarcinoma compared to lung cancer overall: 
rs7705526 (ORNIE=1.07, 1.04-1.10; PM=36.5%), rs13167280 (ORNIE=1.05, 1.03-1.07; PM=24.8%), 
and rs2736108 (ORNIE=1.04, 1.03-1.06; PM=22.9%). 
DISCUSSION 
We observed an association between genetic determinants of long telomeres and increased 
risk of lung, but not head and neck cancers. Our findings lend support to a causal relationship between 
longer leukocyte TL and increased risk of lung adenocarcinoma, but not squamous or small cell 
carcinoma. The magnitude of the increased risk was larger in never smokers and participants aged 
50 or younger, consistent with a stronger influence of genetic susceptibility in individuals with a lower 
burden of modifiable risk factors (52). Although histology and smoking status are closely linked, our 
results suggest that the associations were histology-specific for adenocarcinoma (53, 54). Lastly, our 
mediation analysis demonstrated that mechanisms resulting in long telomeres mediate a proportion 
of the increase in lung cancer and lung adenocarcinoma risk conferred by 5p15.33 loci, and that the 
proportion of genetic susceptibility attributed to telomere maintenance differs between distinct 
5p15.33 susceptibility loci. 
Other analyses using multi-SNP telomere scores have also observed excess risks of lung 
cancer(22-24) and lung adenocarcinoma(22, 24), but did not observe an effect of TL on oral cancer 
risk (23, 24). Opposite directions of effect for the 5p15.33 instrument on lung and HNC are consistent 
with earlier reports of opposing allelic effects for 5p15.33 SNPs on lung and oral cancer, respectively 
(35, 55). Leukocyte TL and functional TERT variants were previously reported to be unrelated to 
squamous HNC risk(56), although one study linked short TL to increased HNC risk based on 
rs2736100, which may be an invalid instrument(22, 57). With the exception of the 5p15.33 IV, the 
instruments used in this study overlap with those used in other MR analyses of TL (22-24). 
Our findings lend support to the hypothesis that a greater number of telomere-increasing 
alleles increase lung cancer susceptibility. Although the precise molecular mechanisms remain to be 
elucidated, telomere maintenance may promote carcinogenesis by enabling prolonged cell survival 
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and accumulation of mutations. This is supported by the hallmark observation that telomerase is 
overexpressed in 85-90% of adult tumors(8, 58), as well as recent data showing that long telomeres 
increase chromosomal instability(59) and promote immortalization of cancer cells(60). Excessively 
long telomeres may also be more fragile and dysfunctional, which is supported by the observation 
that TERT not only replenishes telomeres, but also regulates a trimming process to maintain TL 
homeostasis (61-63).   
Differences in the effect of TL persisted after stratifying by smoking status, suggesting that 
underlying mechanisms differ across tissues and histological types. Longer TL does not appear to 
increase risk of small cell lung cancer or squamous lung carcinoma, the histology that also comprises 
90% of HNC tumours, and for which the causal effect of tobacco smoking is the strongest(64). Since 
our genetic instruments are unrelated to smoking, confounding is unlikely to account for these 
differences. It is plausible that genetic predisposition for telomere maintenance offers some protection 
against genomic instability due to oxidative stress, declining regenerative capacity and immune 
function(7, 65, 66). Although human papillomavirus (HPV), a known cause of oropharynx cancer(67), 
has been reported to correlate with TL(31), the similarity of associations observed for oropharynx and 
oral cancers, only 2% of which are attributed to HPV(68), suggests that HPV infection is unlikely to 
modify the influence of TL.  
This analysis has several important strengths. Genetic instruments represent are unaffected 
by reverse causality and are more likely to reflect causality due to the independence of genotypes 
from confounding factors. In addition to the large sample size, our analysis leveraged rich genetic 
data in 5p15.33, including rare sequence variations, to develop a robust, novel instrument. 
Furthermore, the use of multiple genetic instruments from essential genes for telomere maintenance 
mitigates the possibility for weak instruments bias and genetic confounding due to pleiotropy. The 
association between genetic predisposition to long TL and increased lung cancer risk persisted in 
analyses using the weighted median and mode-based estimators, which further supports the causal 
interpretation of these results. 
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Our mediation analysis offers insight not only by validating the new 5p15.33 instrument, by 
demonstrating an absence of direct effects, but also by formally quantifying the contribution of 
telomere-related mechanisms to the observed association between the established lung and 
adenocarcinoma susceptibility loci and lung cancer risk in this region. Although we confirmed that TL 
is an important molecular mechanism underlying the associations observed for 5p15.33 lung cancer 
risk loci, our results also indicated that only a fraction of these genetic effects operate through 
telomere maintenance. For instance, only 3-8% of the total effect of rs421629 (CLPTM1L) was 
mediated TL, and approximately half of the association between the TERT loci and lung cancer risk 
can be attributed to telomere mechanisms.  
These findings are consistent with our knowledge that 5p15.33 is a complex susceptibility 
locus for multiple cancers(33, 55, 69) and GWAS peaks in this region also encompass non-cancer 
traits, such as red blood cell counts, prostate-specific antigen levels, and lung diseases(69-72). In 
addition, non-canonical functions of TERT, related to proliferation and differentiation via regulation of 
Wnt/ȕ-catenin and Myc signaling, have been proposed(73). Therefore, although telomere 
maintenance is clearly an important 5p15.33 mechanism, cancer susceptibility loci in this region likely 
invoke additional pathways. 
Several limitations of this work should be acknowledged. The time lag between genotype 
assignment at conception and the assessment of genetic effects on TL and cancer risk, as well as 
the time-varying nature of TL, pose challenges for interpreting MR estimates of the causal effect (74). 
However, while genetic instruments do not recapitulate all aspects of telomere function and dynamics, 
they can still provide a valid test of the causal hypothesis that inherited predisposition to telomere 
maintenance increases lung cancer susceptibility (75). Secondly, genetic instruments for leukocyte 
TL may not be accurate proxies for TL in target tissues, which would reduce the power of our genetic 
instruments. However, the validity of instruments based on leukocyte TL is supported by correlation 
between TL in leukocytes and other tissues, including lung, and comparable rates of telomere 
shortening across somatic tissues (76-78). Thirdly, our MR analysis may be affected by winner's 
curse, with the magnitude and strength of association with TL observed in the discovery dataset likely 
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to be exaggerated, particularly the 5p15.33 instrument. However, since the instrument discovery and 
MR analysis populations are independent, any potential bias in the causal parameter GXHWRZLQQHU¶V
curse or limited instrument strength will be towards the null (79). A related concern involves our ability 
to detect subtle effects of TL on cancer risk due to the modest proportion of variation in TL explained 
by our genetic instruments (approximately 5%), which is comparable to most genetic instruments for 
complex phenotypes (80-82). Based on our power calculations, this analysis was adequately 
powered (>80%) to detect effects with OR of 1.5 and above for all lung and HNC histological subtypes 
and smoking-stratified analyses.  
Lastly, the validity of our mediation analysis depends in part on the validity of the published 
estimates of the mediator-outcome relationship. MR-based estimates of the mediator-outcome 
relationship are likely to satisfy the assumption of no unmeasured confounding, but must assume that 
all instruments used in Zhang et al. (22) were valid. While observational studies are more susceptible 
to confounding and bias due measurement error in the molecular mediator (83), a synthesis of 
prospective studies provides complementary evidence that does not depend on MR assumptions, 
and is less vulnerable to reverse causation than case-control designs.  
In summary, we demonstrated that genetic determinants of long telomeres are associated 
with an increased risk of lung cancer, particularly adenocarcinoma. The associations observed for 
HNC were less consistent with a causal relationship, however we cannot preclude the possibility of a 
very subtle telomere effects (OR<1.5). Using mediation analysis that incorporates independent 
published data, we validated the novel 5p15.33 instrument and quantified the proportion of the lung 
cancer association signal in 5p15.33 that is mediated by TL. While this work provides insight into the 
role of TL in cancer etiology, further research is needed to identify appropriate ways of utilizing this 
complex biomarker in the context of disease prevention or clinical intervention. 
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